Sentences with word «allogenic»

Since our flow cytometric data had shown that the HPCs poorly expressed MHC antigens [17], we wondered whether they stimulate allogenic MRL splenocytes (H2k).
Our data show, for the first time, the efficacy of ES - derived CD45 + HPCs to engraft in allogenic recipients without the use of immunosuppressive agents, there by protecting cardiac allografts from rejection.
Delayed cell injection of allogenic mesenchymal progenitor cells for bone regeneration in an ovine critical - sized segmental tibial bone defect.
To determine whether HPCs stimulate allogenic T cells, MRL splenocytes were co-cultured with irradiated 129SvJ splenocytes, HPCs, or bone marrow cells.
Splenocytes and bone marrow cells, but not HPCs, robustly stimulated allogenic T cells to proliferate (C).
Autologous vs. allogenic mesenchymal progenitor cells for the reconstruction of critical sized segmental tibial bone defects in aged sheep.
Patients with fatal blood cancers like leukemia often require allogenic stem cell SCT to survive.
Based on the low immunogenicity of the HPCs in the mixed lymphocyte cultures, we now wondered whether the HPCs would engraft in allogenic recipients.
In allogenic pregnancies, they found that the immune system is more suppressed than in syngenic pregnancies.
So, using mice, Gabriel and Arck also studied allogenic pregnancies, in which the fetuses differ genetically from the mother.
Dr. Soosan Jacob demonstrates a novel technique using corneal allogenic intrastromal ring segments for treating keratoconus in this 1 - Minute Video.
A Phase III Randomized Open - Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid - Refractory Chronic Graft vs Host Disease after Allogenic Stem Cell Transplantation (REACH 3)
Keynote: Convergence of delayed allogenic cell injection in a scaffold - based bone engineering therapy concept.
Delayed minimally invasive injection of allogenic bone marrow stromal cell sheets regenerates large bone defects in an ovine preclinical animal model.
Approval for our trial demonstrated that regulatory agencies are amenable to this type of therapy, and enabled us to start a trial in 2017 for our lead therapy, CYP - 001, in the indication of graft vs. host disease, which marks the world's first clinical trial of allogenic iPSC - derived MSCs.
To improve our understanding and to build better and more translatable in vivo mouse tumor models, we are developing humanized mouse models consisting of the transplant of patient - derived tumor xenografts into immunodeficient mice reconstituted with human immune cells (isolated from the matching patient from the draining LNs or with allogenic PBMCs or LN cells).
Although a number of groups have already looked at the engraftment of ES - derived HPCs in Rag2 − / − γc − / − mice, there are no reports on HPC engraftment in either syngeneic or allogenic immunocompetent mice.
Transplanted syngeneic and allogenic animals were sacrificed at either 40 or 100 days post-transplantation and the histology of the grafts studied after H & E staining.
In addition to the high degree of pluripotency, ES cells can generate newly - differentiated cells that appear to have low immunogenicity, an ideal property for allogenic transplantation.
For these reasons, conditioning recipients of allogenic ES cell - derived HPCs could potentially be safer and less rigorous than conditioning recipients of bone marrow cells.
The lack of a difference between the syngeneic 129SvJ and allogenic MRL mice suggested that the decline in the donor cells was not due to rejection, but rather to out - competition of the HPCs by autologous bone marrow cells.
Indeed, HPCs failed to stimulate allogenic T cells in proliferation assays, in contrast to splenocytes and bone marrow cells.
HPCs failed to stimulate allogenic T cells (Figure 1c), in contrast to splenocytes and bone marrow cells, which robustly stimulated T cells.
As long - term iPSC expansion can give rise to huge amounts of NK cells which are not HLA - restricted, they can serve as an allogenic treatment, this option may allow the treatment of large numbers of patients over a prolonged period of time of required.
The delayed and gradual upregulation of MHC antigens contributed to the immune privilege of these cells in the allogenic setting.
We concluded that these immunological characteristics appeared to favor HPC engraftment in the allogenic setting.
Our findings suggested immunological privilege of HPCs in the allogenic environment.
Long - term engraftment of the allogenic 129SvJ allografts in the MRL mice was observed in all chimeric recipients, but not that of third - party Balb / c allografts.
Here, we confirmed these results by detecting HPC - derived cells in the thymuses of both allogenic and syngeneic mice (data not shown).
Recipient animals were the allogenic MRL (H2k), the immunodeficient Rag2 − / − γc − / − (Taconic) mice or the syngeneic 129SvJ (H2b) mice.
On long - term monitoring, HPC - derived hematopoietic cells remained detectable in both the allogenic and syngeneic mice, albeit declining with time.
Allogenic MRL and control syngeneic 129SvJ mice were sublethally irradiated and subsequently transplanted HPCs.
We therefore transplanted Rag2 − / − γc − / − mice, allogenic MRL mice and syngeneic 129SvJ mice with 2 × 106 HPCs after sublethal irradiation.
Allogenic allografts in chimeric mice were harvested on either day 40 or day 100 - post transplantation.
Despite the allogenic barrier, the MRL mice showed a similar pattern as the syngeneic recipients, suggesting that the engraftment was less likely to be regulated by adaptive immunological factors.
Mice donating cardiac allografts were 8 — 12 week - old 129SvJ mice (H2kb), and the recipients were allogenic MRL mice (H2Kk) of the same age.
a b c d e f g h i j k l m n o p q r s t u v w x y z